Jw
Blood & Organ Banks · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Building B Ke Rd Fl 5 No 699, Zhongwu, C...Phone Number
+86 2150783699Website
www.jwtherapeutics.comRevenue
$23.9 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
4
4
2
About Jw
JW Therapeutics is an independent innovative biotechnology company focused on the development, production, and commercialization of cell immunotherapy products. Established in 2016, the company has created a leading comprehensive product development platform for cell immunotherapy, covering hematological tumors, solid tumors, and autoimmune diseases. JW Therapeutics aims to provide high-quality breakthrough cell immunotherapy products to bring hope for cures to patients in China and globally, while also leading the healthy and standardized development of the cell immunotherapy industry in China. The company is publicly listed on the Hong Kong Stock Exchange under the code 2126.Explore more
Jw Org Chart
Get the full picture
Sign in to uncover key details.
SZ
Associate Medical Director
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jw your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Jw recently announced quarterly report
Click to see if Jw had a recent Job posting/layoffs
Jw, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Jw has recently received funding, and reach out quickly before it becomes old news!
Check out if Jw is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Jw launches new products
Congratulate Masked Content for being promoted to Masked Content at Jw
Funding: Get notified immidiatlly once Jw has new funding data
Recommended Actions
Find VP level buyers at Jw
Find 3 more new buyers
Company Profile Activity
Activity Insights
Jw is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Jw is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Jw.
Jw financials insights
Gather financial insights about Jw, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$90M
2020
Series B
$100M
Jw Tech Stack
A closer look at the technologies used by Jw
Most Recent Scoops
Partnership
Partnership, Product Development, Research & Development, Business Development
Left Company
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Jw News & Media
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers. This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virJW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) granted Breakthrough Therapy Designation for Carteyva® (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphomJW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for thePreliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress
SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel ("relma-cel") injection in adults with active systemic lupus erythematosus ("SLE") in China at the 2024 European Alliance of Associations
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Jw
Sign Up For FreeTo access detailed company insights
JW Therapeutics is an independent innovative biotechnology company focused on the development, production, and commercialization of cell immunotherapy products. Established in 2016, the company has created a leading comprehensive product development platform for cell immunotherapy, covering hematological tumors, solid tumors, and autoimmune disease... Read More
